首页> 外文期刊>The Journal of Clinical Pharmacology: Official Journal of the American College of Clinical Pharmacology >Drug interaction between cimetidine and timolol ophthalmic solution: effect on heart rate and intraocular pressure in healthy Japanese volunteers.
【24h】

Drug interaction between cimetidine and timolol ophthalmic solution: effect on heart rate and intraocular pressure in healthy Japanese volunteers.

机译:西咪替丁和噻吗洛尔滴眼液之间的药物相互作用:对健康的日本志愿者的心率和眼内压的影响。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Systemic adverse effects of timolol ophthalmic solution given at usual therapeutic doses have been well characterized. Timolol is partially metabolized by cytochrome P450 (CYP) 2D6. Cimetidine inhibits the activity of cytochrome P450, including CYP2D6, leading to reduced systemic clearance of concomitant drugs. Coadministration of cimetidine has been speculated to affect the pharmacological effects of timolol ophthalmic solution, resulting in increased blood concentration. To evaluate whether administration of cimetidine with timolol ophthalmic solution increased the degree of beta-blockade, 12 healthy Japanese male volunteers ages 19 to 26 received cimetidine (400 mg), on oral placebo, timolol maleate 0.5% (0.05 mL to each eye), or placebo eye drops in a randomized, double-blind, Latin-square design. The oral drug alone was given for 3 days, and on the 4th day, eye drops were applied after oral drug administration. At baseline and 1, 3, and 6 hours after eye drop administration, blood pressure and heart rate (HR) were measured before and after exercise. Intraocular pressure (IOP) was measured at rest. A visual analog scale (VAS) was used to assess subjective bodily feelings in exercise tolerance after every physical exercise. The exercise HR, exercise systolic blood pressure (SBP), and resting SBP were reduced following timolol with and without cimetidine compared with the placebo (p < 0.01, respectively). Administration of cimetidine with timolol ophthalmic solution resulted in additional reductions of the resting HR and IOP. VAS detected a significant reduction in exercise tolerance from timolol ophthalmic solution (p < .05). In conclusion, administration of cimetidine with timolol ophthalmic solution increased the degree of beta-blockade.
机译:以常规治疗剂量给予的噻吗洛尔滴眼液的全身不良反应已得到很好的表征。替莫洛尔被细胞色素P450(CYP)2D6部分代谢。西咪替丁抑制细胞色素P450的活性,包括CYP2D6,导致伴随药物的全身清除率降低。据推测,西咪替丁的共同给药会影响噻吗洛尔滴眼液的药理作用,从而导致血药浓度升高。为了评估西咪替丁和替莫洛尔滴眼液的使用是否会增加β受体阻滞的程度,年龄为12至26岁的12位健康的日本男性男性志愿者通过口服安慰剂接受西咪替丁(400毫克)口服马来酸替莫洛尔0.5%(每只眼0.05毫升),或安慰剂眼药水,采用随机,双盲,拉丁方形设计。单独口服药物3天,在第4天,口服药物后滴眼液。在基线以及滴眼液给药后1、3和6小时,分别在运动前后测量血压和心率(HR)。静止时测量眼内压(IOP)。每次体育锻炼后,使用视觉模拟量表(VAS)评估运动耐量的主观身体感觉。替莫洛尔加西咪替丁和不加西咪替丁后的运动HR,运动收缩压(SBP)和静息SBP均较安慰剂降低(分别为p <0.01)。西咪替丁与噻吗洛尔滴眼液的联合给药可进一步降低静息HR和IOP。 VAS检测到噻吗洛尔滴眼液的运动耐受性显着降低(p <.05)。总之,将西咪替丁与噻吗洛尔滴眼液一起给药可增加β受体阻滞的程度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号